ABPI: No plans to issue social media rules; Roche meds Mircera, Xenical may run short;

@FiercePharma: NICE to have a "key role" in reviewing genetic tests in U.K., NHS says. News | Follow @FiercePharma

> The Association of the British Pharmaceutical Industry has no plans to issue guidelines for social media use, saying companies can feel free to engage as long as they follow the ABPI Code of Practice. Report

> Roche drugs Mircera and Xenical may run short in some countries because of manufacturing problems at a U.S. plant, the company said. News

> Delaware lawmakers introduced a bill that would require insurance companies to charge similar co-pays for oral and IV cancer drugs, rather than requiring patients to fork over a larger share of the cost for pills. Item

> Warner Chilcott ($WCRX) issued a 2012 forecast that fell short of analyst expectations as it experiences continued declines in sales of its osteoporosis drug Actonel. Story

> A real estate development company, London and Metropolitan, is in "advanced talks" with Pfizer ($PFE) about buying its R&D site in Sandwich, U.K. Piece

> LEO Pharma said its Picato gel has been approved by the FDA for treatment of actinic keratoses. News

> The U.K.'s cost-effectiveness watchdog will play a "key role" in clinical evaluation of new genetic tests, the National Health Service said. Report

Biotech News

@FierceBiotech: Gamers tackle enzyme makeover, beat scientists' efforts. More | Follow @FierceBiotech

@JohnCFierce: 7% of teens and adults have HPV in their mouths, explaining steady rise in oropharyngeal cancer cases--LA Times. Article | Follow @JohnCFierce

@RyanMFierce: BioMarin ($BMRN) shows how stringing together small buyouts (~$20M) in rare diseases could lead to big rewards. More | Follow @RyanMFierce

@MarkHFierce: Researchers have reproduced Alzheimer's disease neurons, in a dish, using stem cells. Could be big research step. Story | Follow @MarkHFierce

> Infinity shutters saridegib cancer study as placebo outperforms in PhII. News

> Westphal pulls off a rare stunt with $55M Verastem IPO. Story

> BioMarin aims to scoop up rare disease drugs as orphan field sizzles. Article

And Finally... Pharma M&A was up to speed in 2011, but licensing deal volume was down, according to a report from PharmaVentures. Report